News articles about TherapeuticsMD (NASDAQ:TXMD) have trended somewhat positive this week, according to Accern. The research firm identifies positive and negative press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. TherapeuticsMD earned a news sentiment score of 0.12 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 45.0391949341088 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

A number of brokerages have recently commented on TXMD. Zacks Investment Research lowered shares of TherapeuticsMD from a “hold” rating to a “sell” rating in a research report on Wednesday, May 3rd. Oppenheimer Holdings, Inc. reissued a “market perform” rating and issued a $12.00 price objective on shares of TherapeuticsMD in a research report on Tuesday, May 9th. CIBC reissued a “market perform” rating and issued a $12.00 price objective on shares of TherapeuticsMD in a research report on Tuesday, May 9th. Cantor Fitzgerald reissued an “overweight” rating and issued a $33.00 price objective on shares of TherapeuticsMD in a research report on Wednesday, May 10th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $20.00 price objective on shares of TherapeuticsMD in a research report on Wednesday, May 24th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $16.14.

Shares of TherapeuticsMD (NASDAQ:TXMD) traded up 0.50% during mid-day trading on Wednesday, hitting $6.03. 1,489,734 shares of the stock were exchanged. The stock’s 50 day moving average price is $5.58 and its 200-day moving average price is $5.54. TherapeuticsMD has a 12-month low of $3.50 and a 12-month high of $8.30. The stock’s market capitalization is $1.23 billion.

TherapeuticsMD (NASDAQ:TXMD) last posted its quarterly earnings data on Thursday, August 3rd. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. The business had revenue of $4.25 million during the quarter, compared to the consensus estimate of $4.91 million. TherapeuticsMD had a negative return on equity of 77.41% and a negative net margin of 462.94%. The firm’s quarterly revenue was down 3.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.11) earnings per share. On average, equities research analysts expect that TherapeuticsMD will post ($0.42) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact TherapeuticsMD (TXMD) Stock Price” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this piece on another publication, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece can be viewed at https://www.watchlistnews.com/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-therapeuticsmd-txmd-stock-price/1532461.html.

About TherapeuticsMD

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Insider Buying and Selling by Quarter for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.